Antioxidant reducing antioxidant reducing

Minimising

reduction

(Decrease)

Kaplan Meier Estimate of

No. of Events (Atorvastatin

Relative Risk

Reduction

vs Placebo)

Absolute Risk

Uncommon Myocardial ischaemia including angina pectoris or myocardial infarction,

Relative risk reduction in

Between treatment comparisons of the incidence of key clinical fracture variables

Risk of rhabdomyolysis is increased when atorvastatin is administered concomitantly with certain medicaments such as ciclosporin, erythromycin, clarithromycin, itraconazole, ketoconazole, nefazodone, niacin, gemfibrozil, other fibric acid derivates or HIV protease inhibitors (see section 4.5 and section 4.8).

Not all included patients were estimated to have a high risk for a first cardiovascular event.

Atorvastatin increased mean HDL C by 2.9 (pravastatin 5.6 , p NS).

Xanthopsia, lacrimation decreased due to hydrochlorothiazide

Reduction 1.

Minification Filter

Aclasta Placebo Absolute reduction in ( ) ( ) fracture incidence (CI)

Noise Reduction...

NoiseReduction

RedEyeReduction

Noise Reduction

a reduction in inequalities,

Relative risk

Primary Efficacy 1)

(N 403)

Number of 150 mg tablets and or 500 mg tablets per

Reduced dose

Activity reduction

Support control led drug use with

Duty reduction

10 reduction

5 reduction

67 reduction

Reduction and replacement

Reduction percentage

reduction catalyst

Reduction for isoglucose

Fee reductions

REDUCING

Reducing

Reduction scheme

Decrease of capacity